Our Pipeline

Targeted Peptides to Detect and Treat Disease at the Source

EndoCyclic Therapeutics is advancing a proprietary peptide platform designed to act only where it matters. Our peptides are selectively absorbed by diseased tissue and engage intracellular targets to activate natural clearance pathways, aiming to restore healthy signaling while sparing surrounding tissue. This targeted mechanism is being developed to support both therapeutic and diagnostic applications with a high margin of safety, avoiding hormones, radiation, or systemic toxicity.

Our investigational pipeline includes first-in-class agents for endometriosis and oncology, with continued development for fibrosis and other women’s health and chronic conditions.

ENDO-205

Non-Hormonal, Disease-Modifying Therapeutic for Endometriosis

ENDO-205 is a first-in-class investigational therapeutic being developed to target endometriosis lesions at their origin, without hormones, surgery, or systemic toxicity. Our studies demonstrate that ENDO-205 can eliminate endometriotic lesions at their origin, offering the potential for true disease resolution.

Short-course treatment under investigation for full and durable lesion clearance
Designed to preserve fertility and avoid hormonal suppression
Targeted mechanism, selectively absorbed by diseased tissue

FemLUNA

Non-Invasive, Definitive Imaging Diagnostic for Endometriosis

FemLUNA is an investigational imaging agent being developed to enable early, accurate, and non-invasive detection of all subtypes of endometriosis, including superficial and sub-millimeter lesions that may be missed by current imaging methods. It is designed for compatibility with both traditional and mobile systems.

Developed to visualize all lesion subtypes, including those difficult to detect with standard imaging
Radiation-free, non-hormonal, and free of heavy metals
Intended for use across sensitive populations, including adolescents and reproductive-age women
Compatible with standard and low-field imaging platforms

ENDO-995

Targeted Therapeutic for Malignant Solid Tumors

ENDO-995 is a novel, investigational non-hormonal therapeutic peptide in development for malignant solid tumors, with an initial focus on colon and endometrial cancers and potential applicability across more than 25% of all solid tumor types. ENDO-995 is designed to improve patient outcomes, enhance quality of life, minimize side effects, and reduce dependence on cytotoxic chemotherapy.

Targets malignant solid tumors with tumor-specific selectivity
Designed to overcome therapeutic resistance and restore responsiveness in cold tumors
Unlocks access to previously undruggable intracellular targets in clinically validated pathways through selective peptide engineering

ENDO-311

Imaging Diagnostic for Malignant Solid Tumors

ENDO-311 is an innovative, investigational imaging agent in development for the non-invasive detection and monitoring of malignant solid tumors, with an initial focus on colon cancer. It is designed to enable early and precise visualization of tumor activity to support improved diagnosis, staging, and treatment planning.

Radiation-free, non-hormonal, and free of heavy metals
Compatible with standard imaging systems
Designed for early-stage tumor localization and disease monitoring

Future Applications

Building on the versatility of our platform, we are actively exploring additional indications where non-hormonal, tissue-specific targeting is essential. These include fibrosis, polycystic ovary syndrome (PCOS), uterine fibroids, and other chronic conditions with limited safe treatment options. We are also developing image-guided surgery agents for real-time visualization during minimally invasive procedures, as well as blood-based diagnostics to track treatment response and support biomarker-driven patient stratification.